New hope for kids with liver fluke: drug dose trial launched
NCT ID NCT07262814
First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests different doses of a new drug, arpraziquantel, in 125 children aged 6-7 who have a liver fluke infection called Opisthorchis viverrini. The goal is to find the dose that cures the most children with the fewest side effects. Children will provide stool samples before and after treatment to see if the infection is gone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPISTHORCHIS VIVERRINI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lao Tropical and Public Health Institute (Lao TPHI)
Vientiane, Laos
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.